Starving tumor cells slows down prostate cancer

Dunya News

Researchers have hit upon a potential treatment for prostate cancer.

The study, conducted with lab grown human cells, reveals targets for drugs that could slow down early and late stage prostate cancer.Current therapies include surgical removal of the prostate, radiation, freezing the tumour or cutting off testosterone supply, but there are often side effects, including incontinence (repeated urge to urinate) and impotence, reports the journal Cancer Research.Growing cells need an essential nutrient, an amino acid called leucine, which is pumped into the cell by specialised proteins. And this could be prostate cancers weak link.Jeff Holst and his team at the Centenary Institute found that prostate cancer cells have more pumps than normal. This allows the cancer cells to take in more leucine and outgrow normal cells, according to a Centenary statement.This information allows us to target the pumps - and weve tried two routes. We found that we could disrupt the uptake of leucine firstly by reducing the expression amount of the protein pumps, and secondly by introducing a drug that competes with leucine.Both approaches slowed cancer growth, in essence starving the cancer cells, Holst says.Study co-author Qian Wang says by targeting different sets of pumps, the researchers were able to slow tumour growth in both the early and late stages of prostate cancer.